Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Investor Day (June 2026)
41 slides from Glenmark Pharmaceuticals's investor day presentation, Jun 9, 2026
Slide 1: Exchange filing cover letter: Investor Day Presentation
June 09, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), Mumbai P.J. Towers, Dalal Street, – 400 051 Mumbai – 400 001 Scrip Nam
Slide 2: Redefining the Future: Investor Day 2026
Redefining the Future Building a Global Innovation-led Pharmaceutical Company Investor Day 2026 Tuesday, 9 June 2026
Slide 3: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Limited and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all state
Slide 4: Today's Agenda
Today’s Agenda Redefining the Future: Building the Next Glenmark Glenn Saldanha Chairman & Managing Director Scaling Global Growth Engines Marc T. Kikuchi President & Business Head – North America Winning in Three Global Therapy Areas Nishan de Silva, M.D. Global Strategy Advisor Advancing Innovatio
Slide 5: Redefining the Future: Building the Next Glenmark
Redefining the Future Building the Next Glenmark Glenn Saldanha Chairman & Managing Director
Slide 6: Differentiated Global Platform for Long-term Value Creation
Differentiated Global Platform for Long-term Value Creation To emerge as a Leading, Research-led, Global pharmaceutical company Large Scale Focused Diversified ~US$2bn >60% >80 revenue contribution from consolidated revenue1 countries with presence Branded portfolio3 ~17,000 3 11 global employee bas
Slide 7: Proven Track Record of Driving Innovation for Over Two Decades
Proven Track Record of Driving Innovation for Over Two Decades Set up NCE R&D Established first Foundational Out-licensed the OX40 centre at Navi NBE R&D Centre in BEAT® protein portfolio to Astria IND filing for Mumbai, India Switzerland platform Therapeutics# ISB 2301 2000 2004 2006 2011 2014 2021
Slide 8: Glenmark Today: A Strong Foundation for Long-term Success
Glenmark Today: A Strong Foundation for Long-term Success Robust Branded business in Substantial US generics Leading generic R&D India & Emerging Markets business & a sizable presence capabilities in Respiratory & in European markets Injectables Exceptional Innovative IGI’s world-class Strong financ
Slide 9: Capital Allocation Strategy Aimed at Value-Chain Enhancement
Capital Allocation Strategy Aimed at Value-Chain Enhancement Strategic Focus Areas Key Investment Decisions To Further Propel Growth • India & Emerging Markets: Expand presence across branded products in key therapeutic areas Base Business • USA: Strengthen existing Respiratory & Injectable platform
Slide 10: Strategic Roadmap to Achieve Long-term Vision
Strategic Roadmap to Achieve Long-term Vision 2030 – 2035 Become a Leading, Global, 2026-2030 Innovation-driven company • Achieve Therapy Area dominance in Dermatology, Respiratory and Oncology • Globally commercialize 1-2 multispecific in India & Emerging Markets innovative products from IGI’s Onco
Slide 11: Scaling Global Growth Engines
Scaling Global Growth Engines Marc T. Kikuchi President & Business Head – North America
Slide 12: Well Diversified Business Through Global Commercial Footprint
Well Diversified Business Through Global Commercial Footprint Emerging India Europe North America Markets Revenue ~25% ~29% Contribution1 ~22% ~24% Russia / CIS, LATAM, Key Markets WEU, CEE USA, Canada MEA, APAC Key Focus Areas2 Respiratory, Dermatology, Oncology 1. As per FY27e consolidated revenue
Slide 13: India: Market-beating Performance Through Strong Brand-building
India: Market-beating Performance Through Strong Brand-building Growth 1.5x above IPM over the last 3 years1 Sharp focus on core therapeutic areas2 % growth FY22 FY26 Overall IPM 15th 13th As per growth rate3 5th 2nd Dermatology 2nd 2nd Respiratory 4th 3rd Apr-23 Jul-23 Oct-23 Jan-24 Apr-24 Jul-24 O
Slide 14: India: Initiatives Aimed at Supporting the Strong Base
India: Initiatives Aimed at Supporting the Strong Base Scale up the Oncology franchise anchored by innovative launches Expand field-force across existing therapeutic areas to deepen market coverage Launch differentiated products to drive growth in Chronic Respiratory & Cardiac Drive turnaround momen
Slide 15: Emerging Markets: Building Through Scale, Reach & Partnerships
Emerging Markets: Building Through Scale, Reach & Partnerships Strong foundation through incremental expansions Large market Strong current positioning with opportunity multiple tailwinds Revenue (₹ million) ~12% • Strong Dermatology, Respiratory franchises Russia / CIS >US$20bn • Multiple leading b
Slide 16: Emerging Markets: Fastest Growing Market in the Next Five Years
Emerging Markets: Fastest Growing Market in the Next Five Years Strengthen Oncology front-end capabilities in core markets to commercialize innovative portfolio Expand field-force across Respiratory & Dermatology to gain additional share Strengthen geographic reach through selectively expansion in a
Slide 17: Europe: Building a Higher-value Growth Platform
Europe: Building a Higher-value Growth Platform Leading growth Direct footprint Increasing share Successful region in the last in five major of branded expansion into five years markets products Respiratory Revenue (₹ million) FY211 RYALTRIS® Glenmark presence 3rd party business Branded SALMEX® ~20%
Slide 18: Europe: Scaling the Next Phase of Growth
Europe: Scaling the Next Phase of Growth Launch additional Respiratory products to gain leadership position in key markets Strengthen RYALTRIS® position in key markets and drive market share gains Successfully launch WINLEVI® and other companion products to strengthen the Dermatology franchise Pursu
Slide 19: North America: At an Inflection Point
North America: At an Inflection Point Leading Leading company generic Well diversified Business has a well Leadership in Differentiated company in the region in the region diversified portfolioportfolio commercialization expansion Revenue contribution3 >86 million #1 Two generic Respiratory total pr
Slide 20: North America: Strengthening Core Areas to Support Growth
North America: Strengthening Core Areas to Support Growth Continue launch momentum in Respiratory (2-3 launches in FY27e) and file additional 2-3 products every year Scale Monroe injectables through increased filing & launch momentum; Continued investment for capacity expansion over the next 3-5 yea
Slide 21: Winning in Three Global Therapy Areas
Winning in Three Global Therapy Areas Nishan de Silva, M.D. Global Strategy Advisor
Slide 22: Building Deep Expertise in Three Key Therapeutic Areas
Building Deep Expertise in Three Key Therapeutic Areas Respiratory Dermatology Oncology • Ranked 3rd in India1 and 3rd in • Ranked 2nd in India1 and 8th in • Ranked among Top 5 Indian Russia1; among the leading Russia1; among the leading companies3 companies in LATAM2 companies in the APAC region2 •
Slide 23: RYALTRIS®: From Vision to Global Leadership
RYALTRIS®: From Vision to Global Leadership >6mn >90 >10 US$300mn patients prescribed filings across the globe; strategic partnerships cumulative global sales globally till date 56 approvals received1 with leading companies as of FY262 Global Sales Performance Robust secondary sales growth in FY26 E
Slide 24: Innovative Brands Driving the Next Phase of Growth
Innovative Brands Driving the Next Phase of Growth Respiratory Dermatology Oncology Trastuzumab Aumolertinib Rezetecan Allergic Acne Plaque NSCLC1, NSCLC, BTC, HER2 Indication Rhinitis Vulgaris Psoriasis CLL2 NSCLC MSI-H tumours tumours3 Key Europe, Global Global India India & Emerging Markets Regio
Slide 25: Evolving Toward a Branded, Innovation-Led Portfolio
Evolving Toward a Branded, Innovation-Led Portfolio FY26 FY30e FY30e Branded portfolio split ~30% ~60% >70% Innovative / Specialty Generics1 Branded2 Branded Generics Differentiated launches to drive consistently high growth in branded markets 1. “Generics” include revenue from North America and res
Slide 26: Advancing Innovation in Next-Gen Biologics
Advancing Innovation in Next-Gen Biologics Lida Pacaud, M.D. President & Chief Executive Officer
Slide 27: Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology
Clinical-Stage Biotechnology Company at the Forefront of Innovation in Oncology OUR MISSION OUR VISION “To provide curative therapies that extend and improve lives.” “We dare to imagine a world where cure is possible.” Innovative Biotech Biologics Discovery Engine Robust Pipeline • Core capabilities
Slide 28: Multispecific Antibodies Will Drive the Next Wave of Innovation in Oncology
MultispecificTM Antibodies Will Drive the Next Wave of Innovation in Oncology 1990s 2010s 2014 2017 TARGETED THERAPIES IMMUNO-ONCOLOGY BISPECIFIC ANTIBODIES CAR-T CELLS FC Function-based Checkpoint and Innate CD3 T-cell engagers Engineered T cells Tumor Killing Immunity Modulators Next Wave MULTISPE
Slide 29: Diversity of Immune Cell Engagement Across Hematologic & Solid Tumour Indications
Diversity of Immune Cell Engagement Across Hematologic & Solid Tumour Indications, and Autoimmune Diseases ONCOLOGY ASSET DESCRIPTION INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RIGHTS CD38 x BCMA x CD3 Multiple ISB 2001 (ABBV-2001) Trispecific Myeloma T -cell engager Multispecific immu
Slide 30: ISB 2001 /ABBV-2001 Trispecific T-cell Engager in Multiple Myeloma
ISB 2001 /ABBV-2001 Trispecific T- cell Engager in Multiple Myeloma Targeting CD38 x BCMA x CD3 Ph1 TRIgnite-1 Study Progressing Rapidly with The Goal to Determine RP2D by 4Q 2026 • To date, >145 subjects have been dosed in the TRIgnite-1 Phase 1 study (42 in dose escalation and >100 in dose expansi
Slide 31: ISB 2301: a First-in-Class Multispecific Immune Cell Activator
ISB 2301: a First-in-Class Multispecific Immune Cell Activator Targeting Solid Tumors Triple TAA targeting • Next-generation multispecific antibody targets three tumour- associated antigens (TAAs), activating both T cells and natural killer (NK) cells • IGI’s clinically validated BEAT® platform enab
Slide 32: Investment Outlook
IGI well poised to remain self-sustaining going forward Strategic Revenue Streams Investment Outlook Diversified income over the next Focused capital allocation: few years through: • ISB 2301 IND filing to be • Development and regulatory completed by end-CY26 milestones payments expected from partne
Slide 33: Creating Long-term Shareholder Value
Creating Long-term Shareholder Value Anurag Mantri Executive Director & Global Chief Financial Officer
Slide 34: Delivering on Strategic & Financial Commitments
Delivering on Strategic & Financial Commitments Criteria Investor Day 2022 Guidance Achievement Revenue 10-12% growth over next 3-4 years ~12% CAGR between FY22-FY26 Branded Business ~2/3rd of consolidated revenue to be On track >60% revenue from branded markets Contribution contributed by branded m
Slide 35: Well Positioned for a Changing Macro Environment
Well Positioned for a Changing Macro Environment Key Risks & Business Impact Ongoing Mitigations • Drag on overall top-line growth • Increased scale in existing Growth Slowdown in branded markets Markets • Negative impact on operating • Higher contribution of innovative margins products • Transition
Slide 36: Structural Margin Improvement Through Portfolio Enhancement & Operating Leverage
Structural Margin Improvement Through Portfolio Enhancement & Operating Leverage EBITDA Margin Trajectory Key Drivers Increased contribution from Branded Portfolio ~23% 21-22% Higher branded contribution → structurally better gross margins Broad-based Growth Expansion in Key Regions Incremental inve
Slide 37: Stronger Balance Sheet Creating Financial Flexibility
Stronger Balance Sheet Creating Financial Flexibility Net Debt Trajectory Return on Investment Profile ₹ million Return on Capital Employed (ROCE)2 Return on Equity (ROE)3 33,743 >23% >20% ~18% ~16% 4,890 -11,763 FY20 FY25 FY26 Current Ratings: • S&P: BB+ (stable) Peer Avg.1 Glenmark Peer Avg.1 Glen
Slide 38: Well Defined Path to Deliver Substantial Shareholder Value
Well Defined Path to Deliver Substantial Shareholder Value Driver Medium-term Outlook • Broad-based growth with greater contribution from branded markets Growth • Revenue Growth: 13-15% CAGR • Growth initiatives with shorter payback periods and superior returns Profitability • Target ~1% margin impr
Slide 39: Thank You
Thank You Investor Day 2026 Tuesday, 9 June 2026
Slide 40: Q&A Session
Q&A Session Investor Day 2026 Tuesday, 9 June 2026
Slide 41: Appendix: Abbreviations
Appendix Abbreviation Full Form Abbreviation Full Form AD Atopic Dermatitis ICANS Immune effector Cell-Associated Neurotoxicity Syndrome ADC Antibody-Drug Conjugate IGI Ichnos Glenmark Innovation APAC Asia-Pacific IPM Indian Pharmaceutical Market BEAT Bispecific Engagement by Antibodies based on the